蒙古国四种新冠初免程序后BNT162b2加强针的一年抗体动力学与有效性
该前瞻性观察研究纳入蒙古国乌兰巴托311名完成同源两剂初免(BBIBP-CorV、ChAdOx1 nCoV-19、Gam-COVID-Vac或BNT162b2)的成人,在第二剂后中位189天接种BNT162b2加强针并随访12个月。结果显示各初免组抗体应答在加强后第14天达峰并至第365天下降,疫苗有效性随时间从1个月至12个月下降,反应原性主要为轻至中度。
要点
- BNT162b2加强针在四种初免程序后均诱导强体液应答,第14天达峰后12个月内下降。
- 针对SARS-CoV-2感染的有效性在加强后早期最高,随访后期降低。
- 加强针反应原性主要为轻至中度。
核心结论
- 异源初免后BNT162b2加强针诱导的体液应答在12个月内下降,疫苗有效性随时间降低。
- 抗体水平与疫苗有效性呈相似时间趋势,但应视为互补结局而非直接因果或正式免疫保护关联。
研究设计与样本
- 前瞻性观察研究,在蒙古国乌兰巴托纳入311名≥18岁成人。
- 受试者完成同源两剂初免(BBIBP-CorV、ChAdOx1 nCoV-19、Gam-COVID-Vac或BNT162b2)后,中位189天(IQR 186-215)接种BNT162b2加强针,按初免程序分组。
- 随访12个月,检测体液免疫应答,监测28天反应原性,通过抗原/侧流试验和/或RT-PCR确定SARS-CoV-2感染。
主要发现
- 所有组抗体应答在第14天达峰并至第365天下降。
- 第14天总抗体浓度最高为BNT+BNT组385.03 U/mL,最低为Gam+BNT组341.74 U/mL。
- 第14天S-RBD IgG最高为BNT+BNT组967.0 ng/mL,最低为BBIBP+BNT组863.70 ng/mL。
- 第14天中和抗体最高为BNT+BNT组368.13 AU/mL和BBIBP+BNT组336.70 AU/mL。
- 随访期间64人感染SARS-CoV-2,其中15人(23.44%)住院;反应原性主要为轻至中度。
关键数值与推荐
- 疫苗有效性从1个月至12个月:BBIBP+BNT从90.54%(95%CI 59.71-97.78)降至71.17%(39.66-86.23)。
- ChAd+BNT从84.97%(49.75-95.51)降至52.59%(8.61-75.41)。
- Gam+BNT从89.68%(23.95-98.60)降至63.84%(15.10-84.60)。
- BNT+BNT从91.89%(40.06-98.90)降至72.29%(34.37-88.30)。
临床怎么用
- 在异源初免人群中,BNT162b2加强针可增强短期体液免疫并降低感染风险。
- 加强针保护随时间下降,需结合当地疫情与人群免疫背景评估后续加强时机。
局限性
- 为观察性研究,疫苗有效性估计基于与未接种组的比较,可能存在混杂。
- 抗体水平与疫苗有效性的相似趋势不应解释为直接因果或免疫保护关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Waning immunity after primary COVID-19 vaccination and the widespread use of heterogeneous vaccine platforms have created uncertainty regarding the durability of protection following booster vaccination. Mongolia implemented a mixed-platform vaccination program and deployed BNT162b2 as a booster. We evaluated the immunogenicity, effectiveness, and safety of a BNT162b2 booster following four primary vaccination regimens with 12 months follow-up. METHODS: In this prospective observational study in Ulaanbaatar, Mongolia, adults (≥18 years) who had completed a homologous two-dose primary series with BBIBP-CorV, ChAdOx1 nCoV-19, Gam-COVID-Vac, or BNT162b2 received a BNT162b2 booster a median of 189 days (IQR 186-215) after the second dose and were grouped according to their primary vaccination regimen. Humoral immune responses (anti-SARS-CoV-2 N/S1-RBD IgG, S-RBD IgG, and neutralizing antibodies) were measured at baseline and at multiple time points up to 12 months after booster vaccination. Reactogenicity was monitored for 28 days. SARS-CoV-2 infection was ascertained by a positive antigen/lateral-flow test and/or RT-PCR. VE was estimated for prespecified follow-up intervals by comparing the risk of SARS-CoV-2 infection in each boosted group with that in an unvaccinated comparison group. FINDINGS: Among 311 participants (mean age 41.88 years [SD 13.64]; 175 [56.27%] women and 136 [43.73%] men), antibody responses peaked at day 14 and declined through day 365 in all groups. At day 14, total antibody concentrations were highest in BNT + BNT (385.03 U/mL) and lowest in Gam + BNT (341.74 U/mL). S-RBD IgG at day 14 was highest in BNT + BNT (967.0 ng/mL) and lowest in BBIBP+BNT (863.70 ng/mL). Neutralizing antibodies at day 14 were highest in BNT + BNT (368.13 AU/mL) and BBIBP+BNT (336.70 AU/mL). During follow-up, 64 participants acquired SARS-CoV-2 infection and 15 (23.44%) were admitted to hospital. Reactogenicity was predominantly mild-to-moderate, and laboratory parameters were generally within acceptable ranges. Vaccine effectiveness declined from 1 month to 12 months: BBIBP+BNT 90.54% (95% CI 59.71-97.78) to 71.17% (39.66-86.23); ChAd+BNT 84.97% (49.75-95.51) to 52.59% (8.61-75.41); Gam + BNT 89.68% (23.95-98.60) to 63.84% (15.10-84.60); BNT + BNT 91.89% (40.06-98.90) to 72.29% (34.37-88.30). INTERPRETATION: A BNT162b2 booster following diverse primary COVID-19 vaccination regimens induced strong humoral responses that declined over 12 months and showed an acceptable reactogenicity profile. VE against SARS-CoV-2 infection was highest soon after boosting and lower later in follow-up. Although antibody levels and VE showed similar temporal patterns, these findings should be interpreted as complementary outcomes rather than evidence of a direct causal relationship or a formal immunological correlate of protection.
引用
- Bazarjav P, Erdene-Ochir T, Sandagdorj A, et al. One-year antibody kinetics and effectiveness of a BNT162b2 booster after four primary COVID-19 vaccination regimens in Mongolia. Vaccine. 2026. PMID: 42800087. doi:10.1016/j.vaccine.2026.129179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。